The Apex Times
Above the Noise
Business Wire
BusinessChipotle Shares Jump on Reports Starbucks Explored a Possible TakeoverThe Apex TimesBusinessJim Cramer Urges a Broadcom (AVGO) Holder to Hold, Says He Trimmed His Own PositionThe Apex TimesBusinessVerizon, AT&T and T-Mobile shares fall about 6% as SpaceX-linked spectrum push rattles US carrier outlookThe Apex TimesBusinessPepsiCo outlines pressure from input costs and product mix, trims full-year earnings outlookThe Apex TimesBusinessWalmart investors weigh valuation risk as new fulfillment push hits the news cycleThe Apex TimesBusinessStarbucks’ shares hold steady near $93 as stock gains prompt renewed focus on cash generationThe Apex TimesBusinessAmazon’s Alexa “Auto Buy” feature enters a tougher test in OctoberThe Apex TimesBusinessGoldman Sachs trims PepsiCo price target but argues for a “decade of growth” as margins face pressureThe Apex TimesBusinessNvidia shares drop after market questions around OpenAI revenue growthThe Apex TimesBusinessHas the market moved too far on Lockheed Martin, or is the stock simply repricing risk?The Apex TimesBusinessDeere and Yamaha Motor team up to build future side-by-side utility vehiclesThe Apex TimesBusinessVerizon weighs competitive pressure as Starlink Mobile expands via low-band 800 MHz spectrum dealThe Apex TimesBusinessChipotle Shares Jump on Reports Starbucks Explored a Possible TakeoverThe Apex TimesBusinessJim Cramer Urges a Broadcom (AVGO) Holder to Hold, Says He Trimmed His Own PositionThe Apex TimesBusinessVerizon, AT&T and T-Mobile shares fall about 6% as SpaceX-linked spectrum push rattles US carrier outlookThe Apex TimesBusinessPepsiCo outlines pressure from input costs and product mix, trims full-year earnings outlookThe Apex TimesBusinessWalmart investors weigh valuation risk as new fulfillment push hits the news cycleThe Apex TimesBusinessStarbucks’ shares hold steady near $93 as stock gains prompt renewed focus on cash generationThe Apex TimesBusinessAmazon’s Alexa “Auto Buy” feature enters a tougher test in OctoberThe Apex TimesBusinessGoldman Sachs trims PepsiCo price target but argues for a “decade of growth” as margins face pressureThe Apex TimesBusinessNvidia shares drop after market questions around OpenAI revenue growthThe Apex TimesBusinessHas the market moved too far on Lockheed Martin, or is the stock simply repricing risk?The Apex TimesBusinessDeere and Yamaha Motor team up to build future side-by-side utility vehiclesThe Apex TimesBusinessVerizon weighs competitive pressure as Starlink Mobile expands via low-band 800 MHz spectrum dealThe Apex TimesBusinessChipotle Shares Jump on Reports Starbucks Explored a Possible TakeoverThe Apex TimesBusinessJim Cramer Urges a Broadcom (AVGO) Holder to Hold, Says He Trimmed His Own PositionThe Apex TimesBusinessVerizon, AT&T and T-Mobile shares fall about 6% as SpaceX-linked spectrum push rattles US carrier outlookThe Apex TimesBusinessPepsiCo outlines pressure from input costs and product mix, trims full-year earnings outlookThe Apex TimesBusinessWalmart investors weigh valuation risk as new fulfillment push hits the news cycleThe Apex TimesBusinessStarbucks’ shares hold steady near $93 as stock gains prompt renewed focus on cash generationThe Apex TimesBusinessAmazon’s Alexa “Auto Buy” feature enters a tougher test in OctoberThe Apex TimesBusinessGoldman Sachs trims PepsiCo price target but argues for a “decade of growth” as margins face pressureThe Apex TimesBusinessNvidia shares drop after market questions around OpenAI revenue growthThe Apex TimesBusinessHas the market moved too far on Lockheed Martin, or is the stock simply repricing risk?The Apex TimesBusinessDeere and Yamaha Motor team up to build future side-by-side utility vehiclesThe Apex TimesBusinessVerizon weighs competitive pressure as Starlink Mobile expands via low-band 800 MHz spectrum dealThe Apex TimesBusinessChipotle Shares Jump on Reports Starbucks Explored a Possible TakeoverThe Apex TimesBusinessJim Cramer Urges a Broadcom (AVGO) Holder to Hold, Says He Trimmed His Own PositionThe Apex TimesBusinessVerizon, AT&T and T-Mobile shares fall about 6% as SpaceX-linked spectrum push rattles US carrier outlookThe Apex TimesBusinessPepsiCo outlines pressure from input costs and product mix, trims full-year earnings outlookThe Apex TimesBusinessWalmart investors weigh valuation risk as new fulfillment push hits the news cycleThe Apex TimesBusinessStarbucks’ shares hold steady near $93 as stock gains prompt renewed focus on cash generationThe Apex TimesBusinessAmazon’s Alexa “Auto Buy” feature enters a tougher test in OctoberThe Apex TimesBusinessGoldman Sachs trims PepsiCo price target but argues for a “decade of growth” as margins face pressureThe Apex TimesBusinessNvidia shares drop after market questions around OpenAI revenue growthThe Apex TimesBusinessHas the market moved too far on Lockheed Martin, or is the stock simply repricing risk?The Apex TimesBusinessDeere and Yamaha Motor team up to build future side-by-side utility vehiclesThe Apex TimesBusinessVerizon weighs competitive pressure as Starlink Mobile expands via low-band 800 MHz spectrum dealThe Apex Times
Back to front
Moderna to return to the Nasdaq-100 as exchange rebalances index lineup
The Apex Times

THE APEX TIMES

Business/The Apex Times/Oct 8, 10:11 PM EDT

Moderna to return to the Nasdaq-100 as exchange rebalances index lineup

Nasdaq said Moderna (MRNA) will be back in the Nasdaq-100 ahead of the October 9 open, after the company was recently removed. The move comes alongside a sharp recent rise in the stock.

By The Apex Times Newsroom2 min readAI-assisted Apex article

Moderna, Inc. is set to rejoin the Nasdaq-100 index before the open on October 9, according to a market report published October 9 by Yahoo Finance. The update follows Moderna’s recent removal from the index, a change that can affect how index-tracking funds allocate capital even when a company’s operating outlook has not shifted.

The report also described Moderna’s trading performance around the announcement period. On October 7, Moderna traded at roughly $196, up 4.81% on the day, and up about 571.42% over the prior 12 months, according to the same coverage.

Index membership decisions are typically based on a mix of eligibility rules and market-based measures that determine whether a stock continues to meet Nasdaq’s standards for inclusion in the Nasdaq-100. While such changes can be closely watched by traders, they are not, by themselves, a announcement of new clinical or commercial developments.

In the Nasdaq-100, inclusion can matter for liquidity and ownership patterns because many exchange-traded funds (ETFs) and institutional mandates track the index’s constituents. When a stock exits and later re-enters, some investors may need to rebalance positions around the effective date, often contributing to short-term demand and price sensitivity.

For Moderna, the re-entry underscores that its stock has remained prominent enough in the market for Nasdaq to restore it to a key large-cap benchmark. The report did not, in the text provided, lay out which specific firm(s) Moderna would replace or the precise index-measure thresholds that triggered the original removal and subsequent return.

Sector context adds to the backdrop. Biotechnology and vaccine-focused companies often experience pronounced market swings driven by expectations around trial results, regulatory milestones, and manufacturing or commercialization progress. Even when fundamentals evolve gradually, index mechanics can amplify the market’s day-to-day focus on relative size and trading characteristics.

What remains unclear from the information provided is the full chain of events between Moderna’s removal and its reinstatement, including any dates for the initial exit, the specific replacement(s) involved, and whether Nasdaq cited particular eligibility metrics in its formal notice. The company also did not provide, in the cited coverage, any accompanying comment explaining the index change from an investor-relations standpoint.

Investors will likely watch the approach to the October 9 open for confirmation of Nasdaq’s effective rebalancing schedule and for any near-term trading impact as benchmark-linked products adjust. The longer-term question will be whether continued stock momentum reflects operational progress, or whether market attention remains dominated by index and portfolio-flow effects.

Why It Matters

  • Index rebalancing can influence short-term trading and ownership patterns, particularly for ETFs and mandates that track the Nasdaq-100.
  • Rapid stock gains, as described in the coverage, may affect eligibility and prompt index committee action even without any immediate fundamental change.
  • For investors, the practical impact is often less about the business narrative and more about portfolio flows around the effective date.
  • The key watch item is whether the reinstatement changes the pace of benchmark-linked buying and selling during the transition window.

Sources

Key Facts

  • Nasdaq is scheduled to have Moderna (MRNA) rejoin the Nasdaq-100 before the October 9 market open, according to Yahoo Finance coverage published October 9.
  • The same report says Moderna was previously removed from the Nasdaq-100.
  • Yahoo Finance reported Moderna traded at about $196 on October 7, up 4.81% on the day.
  • Yahoo Finance also reported Moderna was up about 571.42% over the prior 12 months as of the October 7 trading session.
  • The report did not provide, in the text available here, which specific stock(s) Moderna is replacing when it returns.

Healthcare Related

Moderna to return to the Nasdaq-100 as exchange rebalances index lineup | The Apex Times